Tokyo Tape
Sign in
← Kringle Pharma

Annual report

4884.TEDINET S100UZTE
Period2023-10-01 → 2024-09-30
Filed2024-12-23
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 76
MetricValuePeriodScopeSource row
Revenue¥80m2023-10-01 → 2024-09-30StandaloneNet sales
Revenue¥69m2022-10-01 → 2023-09-30StandaloneNet sales
Revenue¥392m2021-10-01 → 2022-09-30dStandaloneNet sales (5-year summary)
Revenue¥290m2020-10-01 → 2021-09-30dStandaloneNet sales (5-year summary)
Revenue¥468m2019-10-01 → 2020-09-30dStandaloneNet sales (5-year summary)
Operating income−¥818m2023-10-01 → 2024-09-30StandaloneOperating income
Operating income−¥889m2022-10-01 → 2023-09-30StandaloneOperating income
Ordinary income−¥755m2023-10-01 → 2024-09-30StandaloneOrdinary income
Ordinary income−¥853m2022-10-01 → 2023-09-30StandaloneOrdinary income
Ordinary income−¥330m2021-10-01 → 2022-09-30dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥300m2020-10-01 → 2021-09-30dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥116m2019-10-01 → 2020-09-30dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥755m2023-10-01 → 2024-09-30StandaloneIncome before income taxes
Profit before tax−¥853m2022-10-01 → 2023-09-30StandaloneIncome before income taxes
Net income−¥756m2023-10-01 → 2024-09-30StandaloneProfit loss
Net income−¥854m2022-10-01 → 2023-09-30StandaloneProfit loss
Net income−¥332m2021-10-01 → 2022-09-30dStandaloneNet income loss (5-year summary)
Net income−¥301m2020-10-01 → 2021-09-30dStandaloneNet income loss (5-year summary)
Net income−¥118m2019-10-01 → 2020-09-30dStandaloneNet income loss (5-year summary)
Total assets¥2.8bnat 2024-09-30StandaloneAssets
Total assets¥2.6bnat 2023-09-30StandaloneAssets
Total assets¥3.2bnat 2022-09-30dStandaloneTotal assets (5-year summary)
Total assets¥2.6bnat 2021-09-30dStandaloneTotal assets (5-year summary)
Total assets¥2.4bnat 2020-09-30dStandaloneTotal assets (5-year summary)
Total liabilities¥649mat 2024-09-30StandaloneLiabilities
Total liabilities¥597mat 2023-09-30StandaloneLiabilities
Net assets / equity¥2.1bnat 2024-09-30StandaloneNet assets
Net assets / equity¥2.0bnat 2023-09-30StandaloneNet assets
Net assets / equity¥2.8bnat 2022-09-30dStandaloneNet assets
Net assets / equity¥2.5bnat 2021-09-30dStandaloneNet assets (5-year summary)
Net assets / equity¥2.2bnat 2020-09-30dStandaloneNet assets (5-year summary)
Cash and deposits¥2.3bnat 2024-09-30StandaloneCash and deposits
Cash and deposits¥2.1bnat 2023-09-30StandaloneCash and deposits
Cash & equivalents¥1.8bnat 2024-09-30StandaloneCash and cash equivalents
Cash & equivalents¥1.8bnat 2023-09-30StandaloneCash and cash equivalents
Cash & equivalents¥2.5bnat 2022-09-30dStandaloneCash and cash equivalents
Cash & equivalents¥2.1bnat 2021-09-30dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥2.1bnat 2020-09-30dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥661m2023-10-01 → 2024-09-30StandaloneNet cash provided by used in operating activities
Operating cash flow−¥689m2022-10-01 → 2023-09-30StandaloneNet cash provided by used in operating activities
Operating cash flow¥16m2021-10-01 → 2022-09-30dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥561m2020-10-01 → 2021-09-30dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥146m2019-10-01 → 2020-09-30dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow−¥121m2023-10-01 → 2024-09-30StandaloneNet cash provided by used in investment activities
Investing cash flow−¥121m2022-10-01 → 2023-09-30StandaloneNet cash provided by used in investment activities
Investing cash flow−¥254m2021-10-01 → 2022-09-30dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥838m2023-10-01 → 2024-09-30StandaloneNet cash provided by used in financing activities
Financing cash flow¥69m2022-10-01 → 2023-09-30StandaloneNet cash provided by used in financing activities
Financing cash flow¥603m2021-10-01 → 2022-09-30dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥596m2020-10-01 → 2021-09-30dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥2.1bn2019-10-01 → 2020-09-30dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥-118.212023-10-01 → 2024-09-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-158.462022-10-01 → 2023-09-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-68.332021-10-01 → 2022-09-30dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-72.512020-10-01 → 2021-09-30dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-106.72019-10-01 → 2020-09-30dStandaloneBasic earnings loss per share (5-year summary)
Net assets per share¥306.87at 2024-09-30StandaloneNet assets per share (5-year summary)
Net assets per share¥363.45at 2023-09-30StandaloneNet assets per share (5-year summary)
Net assets per share¥517.75at 2022-09-30dStandaloneNet assets per share (5-year summary)
Net assets per share¥578.17at 2021-09-30dStandaloneNet assets per share (5-year summary)
Net assets per share¥599.97at 2020-09-30dStandaloneNet assets per share (5-year summary)
Equity ratio75.8%at 2024-09-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio76.6%at 2023-09-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio86.8%at 2022-09-30dStandaloneEquity to asset ratio (5-year summary)
Equity ratio95.1%at 2021-09-30dStandaloneEquity to asset ratio (5-year summary)
Equity ratio93.1%at 2020-09-30dStandaloneEquity to asset ratio (5-year summary)
Shares issued6,810,700at 2024-09-30StandaloneTotal number of issued shares (5-year summary)
Shares issued5,522,200at 2023-09-30StandaloneTotal number of issued shares (5-year summary)
Shares issued5,380,700at 2022-09-30dStandaloneTotal number of issued shares (5-year summary)
Shares issued4,334,700at 2021-09-30dStandaloneTotal number of issued shares (5-year summary)
Shares issued182,385at 2020-09-30dStandaloneTotal number of issued shares (5-year summary)
Employees15at 2024-09-30StandaloneNumber of employees
Employees13at 2023-09-30StandaloneNumber of employees
Employees12at 2022-09-30dStandaloneNumber of employees
Employees11at 2021-09-30dStandaloneNumber of employees
Employees9at 2020-09-30dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

All source rows · 752
ItemContextValueUnit
Payments into time deposits inv cfPrior1YearDuration_NonConsolidatedMember-120875000JPY
Payments into time deposits inv cfCurrentYearDuration_NonConsolidatedMember-121281000JPY
Net cash provided by used in investment activitiesPrior1YearDuration_NonConsolidatedMember-120875000JPY
Net cash provided by used in investment activitiesCurrentYearDuration_NonConsolidatedMember-121363000JPY
Purchase of treasury stock fin cfPrior1YearDuration_NonConsolidatedMember－JPY
Purchase of treasury stock fin cfCurrentYearDuration_NonConsolidatedMember-31000JPY
Proceeds from issuance of subscription rights to shares fin cfPrior1YearDuration_NonConsolidatedMember1242000JPY
Proceeds from issuance of subscription rights to shares fin cfCurrentYearDuration_NonConsolidatedMember－JPY
Proceeds from issuance of stock resulting from exercise of subscription rights to shares fin cfPrior1YearDuration_NonConsolidatedMember67922000JPY
Proceeds from issuance of stock resulting from exercise of subscription rights to shares fin cfCurrentYearDuration_NonConsolidatedMember838265000JPY
Net cash provided by used in financing activitiesPrior1YearDuration_NonConsolidatedMember69164000JPY
Net cash provided by used in financing activitiesCurrentYearDuration_NonConsolidatedMember838233000JPY
Net increase decrease in cash and cash equivalentsPrior1YearDuration_NonConsolidatedMember-740806000JPY
Net increase decrease in cash and cash equivalentsCurrentYearDuration_NonConsolidatedMember55703000JPY
Cash and cash equivalentsPrior2YearInstant_NonConsolidatedMember2502046000JPY
Cash and cash equivalentsPrior1YearInstant_NonConsolidatedMember1761239000JPY
Cash and cash equivalentsPrior1YearInstant_NonConsolidatedMember1761239000JPY
Cash and cash equivalentsCurrentYearInstant_NonConsolidatedMember1816943000JPY
Accumulated depreciation buildings and accompanying facilitiesPrior1YearInstant_NonConsolidatedMember-7263000JPY
Accumulated depreciation buildings and accompanying facilitiesCurrentYearInstant_NonConsolidatedMember-7263000JPY
Accumulated depreciation tools furniture and fixturesPrior1YearInstant_NonConsolidatedMember-21082000JPY
Accumulated depreciation tools furniture and fixturesCurrentYearInstant_NonConsolidatedMember-21082000JPY
Research and development expenses sgaPrior1YearDuration_NonConsolidatedMember716792000JPY
Research and development expenses sgaCurrentYearDuration_NonConsolidatedMember643266000JPY
Research and development expenses included in general and administrative expenses and manufacturing cost for current periodPrior1YearDuration_NonConsolidatedMember716792000JPY
Research and development expenses included in general and administrative expenses and manufacturing cost for current periodCurrentYearDuration_NonConsolidatedMember643266000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)有価証券報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)近畿財務局長
Filing date cover pageFilingDateInstant2024-12-23
Fiscal year cover pageFilingDateInstant
Original text (Japanese)第23期（自　2023年10月１日　至　2024年９月30日）
Company name cover pageFilingDateInstant
Original text (Japanese)クリングルファーマ株式会社
Company name in english cover pageFilingDateInstantＫｒｉｎｇｌｅ　Ｐｈａｒｍａ，　Ｉｎｃ．
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　　安達　喜一
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)大阪府茨木市彩都あさぎ七丁目７番15号彩都バイオインキュベータ207
Telephone number address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)072-641-8739（代表）
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)取締役経営管理部長　　村上　浩一
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)大阪府茨木市彩都あさぎ七丁目７番15号彩都バイオインキュベータ207
Telephone number nearest place of contact cover pageFilingDateInstant
Original text (Japanese)072-641-8739（代表）
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)取締役経営管理部長　　村上　浩一
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE36129
Fund codeFilingDateInstant－
Security codeFilingDateInstant48840
Filer name in japaneseFilingDateInstant
Original text (Japanese)クリングルファーマ株式会社
Filer name in englishFilingDateInstantKringle Pharma, Inc.
Fund name in japaneseFilingDateInstant－
Fund name in englishFilingDateInstant－
Cabinet office ordinanceFilingDateInstant
Original text (Japanese)企業内容等の開示に関する内閣府令
Document typeFilingDateInstant
Original text (Japanese)第三号様式

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2023-09-30pass
balance sheet identitynon_consolidated 2024-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2022-09-30pass
statement vs summary · net assetsnon_consolidated 2023-09-30pass
statement vs summary · net assetsnon_consolidated 2024-09-30pass
statement vs summary · operating cash flownon_consolidated 2022-10-01/2023-09-30pass
statement vs summary · operating cash flownon_consolidated 2023-10-01/2024-09-30pass
statement vs summary · revenuenon_consolidated 2022-10-01/2023-09-30pass
statement vs summary · revenuenon_consolidated 2023-10-01/2024-09-30pass
statement vs summary · total assetsnon_consolidated 2023-09-30pass
statement vs summary · total assetsnon_consolidated 2024-09-30pass